Stellar Biotechnologies, Inc. (NASDAQ: SBOT) specializes in Keyhole Limpet Hemocyanin (KLH) protein and we are focused in the rapidly-evolving field of immunotherapy.
KLH is an important immune-stimulating molecule widely used as an active pharmaceutical ingredient (API) in many new immunotherapies, and as an injectable product to assess immune response. This versatile molecule has a long history of safe and effective use across a wide range of disease indications (cancer, inflammatory disease, Alzheimer’s, and immune disorders) and research applications.
Stellar is the leader in sustainable manufacture of KLH. We applied decades of specialized aquaculture science to a pharmaceutical industry challenge, and created the only KLH production facility of its kind. Stellar developed the proprietary ability to sustainably produce GMP grade KLH, and we set unprecedented benchmarks for its manufacture and sustainable supply.
Stellar's customers and partners include multinational pharmaceutical companies, renowned research centers, and developers of active immunotherapies and therapeutic vaccines. The complexity and versatility of the KLH molecule, and growing need for commercial-scale GMP grade KLH, provide numerous commercial opportunities for our company.
Stellar’s core business is the manufacture and supply of KLH protein under the brand name Stellar KLH™. Our products include Stellar KLH™ protein in various grades, formulations, and configurations for both clinical and research applications. Stellar KLH™ can be used for therapeutic vaccine conjugation, as a carrier molecule in immunotherapies, and as an immune stimulant in immunotoxicology applications.
We are committed to applying our Stellar KLH™ platform to power the growing field of disease-targeting immune therapies.